https://www.biopharmawatch.com/news/SYK/stryker-joint-replacement-caregivers-bmw-championship BiopharmaWatch en 2026-08-17T15:19:00.000Z Stryker spotlights the joint replacement journey and the vital role of caregivers at the 2026 BMW Championship https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-appoints-carol-brosgart BiopharmaWatch en 2026-08-17T15:17:00.000Z Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors https://www.biopharmawatch.com/news/INCY/global-vitiligo-foundation-supports-incyte-campaign BiopharmaWatch en 2026-08-17T15:14:00.000Z Global Vitiligo Foundation Applauds Incyte’s “Moments of Clarity” Campaign for Elevating Patient Voices and Advancing Vitiligo Awareness https://www.biopharmawatch.com/news/CRBP/corbus-inducement-grants-leonardo-nicacio BiopharmaWatch en 2026-08-17T14:00:00.000Z Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ARWR/redeemplo-available-fcs-patients-germany BiopharmaWatch en 2026-08-17T13:33:00.000Z People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides https://www.biopharmawatch.com/news/MMED/minimed-flex-insulin-pump-shipping BiopharmaWatch en 2026-08-17T13:04:00.000Z MiniMed's Smallest App-Controlled Insulin Pump Now Shipping with the World's Smallest Sensor https://www.biopharmawatch.com/news/PLUR/pluri-ever-after-foods-fishway-acquisition-investment BiopharmaWatch en 2026-08-17T13:00:00.000Z Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment https://www.biopharmawatch.com/news/IGC/igc-pharma-q2-2026-results-calma-trial-update BiopharmaWatch en 2026-08-17T12:55:48.000Z IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer’s Trial Moves Within Six Randomizations of Enrollment Closure https://www.biopharmawatch.com/news/UHS/universal-health-services-acquires-talkspace BiopharmaWatch en 2026-08-17T12:52:00.000Z Universal Health Services, Inc. Completes Acquisition of Talkspace, Inc. https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-notice-allowance-art27-13 BiopharmaWatch en 2026-08-17T12:52:00.000Z Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies https://www.biopharmawatch.com/news/NTHI/nthi-nasdaq-advantage-phase-2a-results BiopharmaWatch en 2026-08-17T12:45:00.000Z NTHI’s Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results https://www.biopharmawatch.com/news/AIDX/2020-biolabs-q2-2026-financial-results BiopharmaWatch en 2026-08-17T12:31:00.000Z 20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-private-placement-nasdaq BiopharmaWatch en 2026-08-17T12:30:00.000Z Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/CVM/cel-sci-reports-fiscal-third-quarter-2026-results BiopharmaWatch en 2026-08-17T12:30:00.000Z CEL-SCI Reports Fiscal Third Quarter 2026 Results https://www.biopharmawatch.com/news/IVF/invo-fertility-q2-2026-results-revenue-growth BiopharmaWatch en 2026-08-17T12:30:00.000Z INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability https://www.biopharmawatch.com/news/TRIB/trinity-biotech-trinovium-echelon-cooling-solutions BiopharmaWatch en 2026-08-17T12:30:00.000Z Trinity Biotech’s Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI Infrastructure https://www.biopharmawatch.com/news/DWTX/dogwood-virtual-kol-event-halneuron-cinp BiopharmaWatch en 2026-08-17T12:30:00.000Z Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026 https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-iso-recertification BiopharmaWatch en 2026-08-17T12:30:00.000Z Intelligent Bio Solutions Strengthens Quality Management Credentials with ISO Recertification https://www.biopharmawatch.com/news/NSRX/nasus-pharma-h1-2026-financial-results-update BiopharmaWatch en 2026-08-17T12:14:00.000Z Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ACXP/acurx-fda-conditional-acceptance-ibezapolstat BiopharmaWatch en 2026-08-17T12:01:00.000Z Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat https://www.biopharmawatch.com/news/URGN/urogen-submits-nda-ugn-103-recurrent-lg-ir-nmibc BiopharmaWatch en 2026-08-17T12:00:00.000Z UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-q2-2026-financial-results BiopharmaWatch en 2026-08-17T12:00:00.000Z ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CON/concentra-strengthens-workforce-health-access-minnesota-acquisition BiopharmaWatch en 2026-08-17T12:00:00.000Z Concentra Strengthens Workforce Health Access in Minnesota Through Acquisition https://www.biopharmawatch.com/news/SVA/sinovac-reports-first-half-2026-financial-results BiopharmaWatch en 2026-08-17T12:00:00.000Z SINOVAC Reports Unaudited First Half of 2026 Financial Results https://www.biopharmawatch.com/news/GCTK/glucotrack-compliance-milestone-strategic-transformation BiopharmaWatch en 2026-08-17T12:00:00.000Z Glucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation https://www.biopharmawatch.com/news/BHC/bausch-health-gastrointestinal-health-scholars-2026 BiopharmaWatch en 2026-08-17T12:00:00.000Z Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners https://www.biopharmawatch.com/news/LH/labcorp-investor-day-september-2026 BiopharmaWatch en 2026-08-17T12:00:00.000Z Labcorp to Host Investor Day on September 10, 2026 https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-baird-2026-healthcare-conference BiopharmaWatch en 2026-08-17T12:00:00.000Z PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026 https://www.biopharmawatch.com/news/NXGL/nexgel-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-17T12:00:00.000Z NEXGEL Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-appoints-aj-joshi-cmo BiopharmaWatch en 2026-08-17T12:00:00.000Z Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer https://www.biopharmawatch.com/news/AVXL/anavex-director-nominees-annual-meeting-2026 BiopharmaWatch en 2026-08-17T12:00:00.000Z Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees https://www.biopharmawatch.com/news/SNN/smith-nephew-flow-flextend-coblation-wand-launch BiopharmaWatch en 2026-08-17T12:00:00.000Z Smith+Nephew’s new FLOW FLEXTEND™ COBLATION™ Wand improves access¹* and resection efficiency²** for complex hip procedures vs. fixed-angle options https://www.biopharmawatch.com/news/EVAX/evaxion-expands-rd-pipeline-evx-05-brain-cancer-vaccine BiopharmaWatch en 2026-08-17T12:00:00.000Z Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program https://www.biopharmawatch.com/news/OSTX/os-therapies-q2-2026-financials-regulatory-updates BiopharmaWatch en 2026-08-17T11:40:00.000Z OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-fda-fast-track-piktor-paclitaxel BiopharmaWatch en 2026-08-17T11:30:00.000Z Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer https://www.biopharmawatch.com/news/CGC/canopy-growth-mailing-proxy-materials-2026-meeting BiopharmaWatch en 2026-08-17T11:30:00.000Z Canopy Growth Announces Mailing of Proxy Materials for 2026 Annual General and Special Meeting – Urges Shareholders to Vote Now https://www.biopharmawatch.com/news/RADX/radiopharm-fda-meeting-phase-3-trial-design-rad101 BiopharmaWatch en 2026-08-17T11:30:00.000Z Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases https://www.biopharmawatch.com/news/CANF/can-fite-namodenoson-enhances-chemotherapy-pancreatic-cancer BiopharmaWatch en 2026-08-17T11:00:00.000Z Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer https://www.biopharmawatch.com/news/UTHR/united-therapeutics-teton-ppf-study-enrollment BiopharmaWatch en 2026-08-17T11:00:00.000Z United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis https://www.biopharmawatch.com/news/PLSM/pulsenmore-ai-grant-smartscan-program BiopharmaWatch en 2026-08-17T11:00:00.000Z Pulsenmore Receives Second AI Grant Within One Month: Israel Innovation Authority Approves $1.27 Million for SmartScan AI Program https://www.biopharmawatch.com/news/CSTL/castle-biosciences-dual-listing-nasdaq-texas BiopharmaWatch en 2026-08-17T11:00:00.000Z Castle Biosciences Approved for Dual Listing on Nasdaq Texas https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-17T11:00:00.000Z InspireMD Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/EYPT/eyepoint-lugano-phase-3-results-duravyu-wet-amd BiopharmaWatch en 2026-08-17T11:00:00.000Z EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-q2-2026-financial-results-update BiopharmaWatch en 2026-08-17T11:00:00.000Z NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET https://www.biopharmawatch.com/news/FULC/fulcrum-slate-merger-next-gen-migraine-therapies BiopharmaWatch en 2026-08-17T11:00:00.000Z Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies https://www.biopharmawatch.com/news/KMDA/kamada-cash-dividend-record-high-revenue-2026 BiopharmaWatch en 2026-08-17T11:00:00.000Z Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026 https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-q2-2026-financial-results-update BiopharmaWatch en 2026-08-17T11:00:00.000Z Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update https://www.biopharmawatch.com/news/IMCC/im-cannabis-agreement-sell-imc-holdings-assets BiopharmaWatch en 2026-08-17T10:32:00.000Z IM Cannabis Enters into Agreement to Sell IMC Holdings and European- Focused Assets https://www.biopharmawatch.com/news/ACH/accendra-health-capital-allocation-ceo-succession BiopharmaWatch en 2026-08-17T10:30:00.000Z Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans https://www.biopharmawatch.com/news/OABI/omniab-raises-2026-financial-guidance BiopharmaWatch en 2026-08-17T10:06:00.000Z OmniAb Raises 2026 Financial Guidance https://www.biopharmawatch.com/news/OABI/omniab-global-collaboration-eli-lilly-ion-channel BiopharmaWatch en 2026-08-17T10:01:00.000Z OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company https://www.biopharmawatch.com/news/ZLAB/zai-lab-argenx-positive-results-efgartigimod-trial BiopharmaWatch en 2026-08-17T10:00:00.000Z Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-08-17 BiopharmaWatch en 2026-08-17T07:15:41.150Z Biotech Catalysts to Watch: Key Developments Ahead for TENX and SION https://www.biopharmawatch.com/news/ARGX/argenx-positive-results-phase-3-alkivia-trial BiopharmaWatch en 2026-08-17T05:00:00.000Z argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis https://www.biopharmawatch.com/news/MESO/mesoblast-completes-patient-treatment-phase-3-trial BiopharmaWatch en 2026-08-17T00:35:00.000Z Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain